INMED PHARMACEUTICALS INC. (INM) Scorecard
- 2026-Q2: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Lose; Revenue growth Lose; EPS growth Lose.
22/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 1 wins, 11 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
WinINM / S&P 140.31% / 15.20% |
LoseINM / S&P INM unavailable / 15.00% |
LoseINM / S&P INM unavailable / 50.40% |
| 2026-Q10/3 |
LoseINM / S&P -39.15% / -4.33% |
LoseINM / S&P INM unavailable / 11.30% |
LoseINM / S&P -82.34% / 27.70% |
| 2025-Q40/3 |
LoseINM / S&P -51.60% / 2.65% |
LoseINM / S&P -6.73% / 9.00% |
LoseINM / S&P -75.57% / 13.40% |
| 2025-Q30/3 |
LoseINM / S&P -32.62% / 8.12% |
LoseINM / S&P -3.27% / 4.61% |
LoseINM / S&P -52.78% / 13.45% |
| 2025-Q22/3 |
WinINM / S&P 57.00% / 10.94% |
WinINM / S&P 7.50% / 4.83% |
LoseINM / S&P -66.70% / 10.63% |
| 2025-Q11/3 |
LoseINM / S&P -56.33% / -4.27% |
WinINM / S&P 72.31% / 4.98% |
LoseINM / S&P -46.29% / 10.57% |
| 2024-Q41/3 |
LoseINM / S&P 0.00% / 2.41% |
WinINM / S&P 77.83% / 5.25% |
LoseINM / S&P -29.48% / 6.15% |
| 2024-Q31/3 |
LoseINM / S&P -10.90% / 5.89% |
WinINM / S&P 154.80% / 5.89% |
LoseINM / S&P -17.06% / 6.11% |
| 2024-Q22/3 |
LoseINM / S&P -26.92% / 4.28% |
WinINM / S&P 236.64% / 5.38% |
WinINM / S&P 395.09% / 5.12% |
| 2024-Q12/3 |
LoseINM / S&P -12.50% / 10.56% |
WinINM / S&P 9.19% / 5.71% |
WinINM / S&P 19.56% / 5.59% |
| 2023-Q41/3 |
LoseINM / S&P -40.57% / 11.69% |
WinINM / S&P 43.68% / 6.81% |
LoseINM / S&P -20.21% / 7.78% |
| 2023-Q31/3 |
LoseINM / S&P -24.49% / -3.27% |
WinINM / S&P 15.43% / 7.52% |
LoseINM / S&P -46.82% / -5.03% |
| 2023-Q20/3 |
LoseINM / S&P -14.17% / 8.74% |
LoseINM / S&P INM unavailable / 9.50% |
LoseINM / S&P -84.01% / -8.57% |
| 2023-Q10/3 |
LoseINM / S&P -46.53% / 7.50% |
LoseINM / S&P INM unavailable / 10.77% |
LoseINM / S&P INM unavailable / -15.69% |
| 2022-Q40/3 |
LoseINM / S&P -69.37% / 7.56% |
LoseINM / S&P INM unavailable / 11.88% |
LoseINM / S&P INM unavailable / -17.99% |
| 2022-Q30/3 |
LoseINM / S&P -43.88% / -4.88% |
LoseINM / S&P INM unavailable / 13.47% |
LoseINM / S&P INM unavailable / -1.41% |
| 2022-Q20/3 |
LoseINM / S&P -50.16% / -16.10% |
LoseINM / S&P INM unavailable / 13.71% |
LoseINM / S&P INM unavailable / 11.04% |
| 2022-Q10/3 |
LoseINM / S&P -28.02% / -4.60% |
LoseINM / S&P INM unavailable / 15.97% |
LoseINM / S&P INM unavailable / 42.23% |
| 2021-Q40/3 |
LoseINM / S&P -25.14% / 11.03% |
LoseINM / S&P INM unavailable / 15.00% |
LoseINM / S&P INM unavailable / 96.40% |
| 2021-Q30/3 |
LoseINM / S&P -44.97% / 0.58% |
LoseINM / S&P INM unavailable / 10.77% |
LoseINM / S&P INM unavailable / 69.42% |
| 2021-Q20/3 |
LoseINM / S&P -3.64% / 8.55% |
LoseINM / S&P INM unavailable / 6.58% |
LoseINM / S&P INM unavailable / 51.81% |
| 2021-Q10/3 |
LoseINM / S&P 0.30% / 6.17% |
LoseINM / S&P INM unavailable / -1.06% |
LoseINM / S&P INM unavailable / 7.39% |
| 2020-Q40/3 |
LoseINM / S&P -2.43% / 12.15% |
LoseINM / S&P INM unavailable / -3.72% |
LoseINM / S&P INM unavailable / -33.42% |
| 2020-Q30/3 |
LoseINM / S&P -45.36% / 8.93% |
LoseINM / S&P INM unavailable / -2.04% |
LoseINM / S&P INM unavailable / -27.10% |
| 2020-Q21/3 |
WinINM / S&P 20.65% / 20.54% |
LoseINM / S&P INM unavailable / -0.46% |
LoseINM / S&P INM unavailable / -27.11% |
| 2020-Q11/3 |
WinINM / S&P -13.89% / -19.60% |
LoseINM / S&P INM unavailable / 3.47% |
LoseINM / S&P INM unavailable / -14.75% |
| 2019-Q40/3 |
LoseINM / S&P -15.89% / 9.07% |
LoseINM / S&P INM unavailable / 5.36% |
LoseINM / S&P INM unavailable / 2.99% |
| 2019-Q30/3 |
LoseINM / S&P -17.05% / 1.70% |
LoseINM / S&P INM unavailable / 5.02% |
LoseINM / S&P INM unavailable / 0.21% |
| 2019-Q20/3 |
LoseINM / S&P -38.13% / 4.30% |
LoseINM / S&P INM unavailable / 6.64% |
LoseINM / S&P INM unavailable / 8.65% |
| 2019-Q11/3 |
WinINM / S&P 63.53% / 13.65% |
LoseINM / S&P INM unavailable / 8.12% |
LoseINM / S&P INM unavailable / 14.29% |
| 2018-Q40/3 |
LoseINM / S&P -58.87% / -13.52% |
LoseINM / S&P INM unavailable / 9.05% |
LoseINM / S&P INM unavailable / 18.23% |
| 2018-Q31/3 |
WinINM / S&P 7.83% / 7.71% |
LoseINM / S&P INM unavailable / 10.21% |
LoseINM / S&P INM unavailable / 19.06% |
| 2018-Q20/3 |
LoseINM / S&P -46.56% / 3.43% |
LoseINM / S&P INM unavailable / 9.03% |
LoseINM / S&P INM unavailable / 14.46% |
| 2018-Q11/3 |
WinINM / S&P 1.03% / -0.76% |
LoseINM / S&P INM unavailable / 7.68% |
LoseINM / S&P INM unavailable / 12.46% |
| 2017-Q41/3 |
WinINM / S&P 166.25% / 6.64% |
LoseINM / S&P INM unavailable / 7.03% |
LoseINM / S&P INM unavailable / 13.82% |
| 2017-Q31/3 |
WinINM / S&P 56.25% / 4.48% |
LoseINM / S&P INM unavailable / 5.68% |
LoseINM / S&P INM unavailable / 17.57% |
| 2017-Q20/3 |
LoseINM / S&P -28.49% / 3.09% |
LoseINM / S&P INM unavailable / 4.83% |
LoseINM / S&P INM unavailable / 17.74% |
| 2017-Q11/3 |
WinINM / S&P 110.59% / 6.07% |
LoseINM / S&P INM unavailable / 3.67% |
LoseINM / S&P INM unavailable / 13.32% |
| 2016-Q41/3 |
WinINM / S&P 70.00% / 3.82% |
LoseINM / S&P INM unavailable / 2.09% |
LoseINM / S&P INM unavailable / 7.05% |
| 2016-Q31/3 |
WinINM / S&P 28.21% / 3.85% |
LoseINM / S&P INM unavailable / 0.20% |
LoseINM / S&P INM unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | INM total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -35.59% | 20.78% |
| Annualized return | -35.59% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | INM total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -99.88% | 83.14% |
| Annualized return | -73.85% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | INM total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -99.87% | 319.30% |
| Annualized return | -48.42% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |